Block E R, Rostand R A
Surv Ophthalmol. 1978 Nov-Dec;23(3):169-72. doi: 10.1016/0039-6257(78)90152-2.
Carbonic anhydrase inhibitors, of proven value in the longterm management of glaucoma, have a number of troublesome side effects, most of which are well-known. However, their potential hazards to patients with chronic obstructive lung disease have received little attention. The author reviews the physiological effects of carbonic anhydrase inhibition on carbon dioxide metabolism and the implications for the chronic lung patient. The untoward pulmonary complications associated with the use of carbonic anhydrase inhibitors are of particular importance to ophthalmologists, since chronic lung disease and glaucoma, both common disorders in the elderly, frequently coexist in the same patient.
碳酸酐酶抑制剂在青光眼的长期治疗中已被证明具有一定价值，但有许多令人烦恼的副作用，其中大多数是众所周知的。然而，它们对慢性阻塞性肺疾病患者的潜在危害却很少受到关注。作者回顾了碳酸酐酶抑制对二氧化碳代谢的生理影响以及对慢性肺病患者的影响。与使用碳酸酐酶抑制剂相关的不良肺部并发症对眼科医生尤为重要，因为慢性肺病和青光眼都是老年人的常见疾病，经常在同一患者中并存。
